NCT03686124 2026-02-18
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
Clinical Trials
3 trialsNCT06581406 2026-02-18
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune Inc.
Phase 2/3 Recruiting
NCT06519266 2024-11-25
SCANDIUM-III
Vastra Gotaland Region
Phase 3 Recruiting